Is Wegovy good for the heart? What the clinical evidence says

What did the SELECT trial find, and why does it matter?

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a large, randomised, placebo-controlled trial running over five years, involving adults who had obesity or overweight, a prior cardiovascular event such as a heart attack or stroke, but no diabetes. That last detail matters: the cardiovascular benefit appeared in people whose blood sugar was already well-controlled, which helps separate the heart effect from any diabetes-related improvement.

Participants on semaglutide 2.4mg experienced roughly a 20% relative reduction in major cardiovascular events (a composite of heart attack, stroke, and cardiovascular death) compared with the placebo group. That result held up even among people who lost less weight than average during the trial. Researchers found no lower threshold of weight loss below which the benefit disappeared, which has led many cardiologists to think semaglutide may act on inflammation, arterial function or other pathways in addition to simply reducing body fat.

The trial result was significant enough that the MHRA granted an additional marketing authorisation: Wegovy in the UK is now licensed both for weight management and for reducing cardiovascular risk in adults with BMI 27 or above and established cardiovascular disease. If you want a thorough grounding in whether Wegovy is good for your heart and what the evidence actually shows, that is covered in detail on a dedicated page. The full trial data are discussed in NICE's technology appraisal of semaglutide (TA875), and the NHS medicines page for semaglutide provides accessible background on how the medicine works.

Does the heart benefit come only from losing weight?

This is the misconception that trips most people up, and it's understandable. The natural assumption is that a weight-loss drug helps the heart simply by taking the pressure off, less weight, less strain on the cardiovascular system. There is truth in that, but the SELECT data gently complicate it.

When researchers analysed subgroups by how much weight participants lost, the cardiovascular benefit did not disappear in those who shed only a small amount. That pattern suggests semaglutide exerts at least some of its heart-protective effect through other mechanisms: reducing systemic inflammation (GLP-1 receptors are present in heart tissue and blood vessel walls), lowering blood pressure, improving lipid profiles, and possibly having direct effects on how the heart responds to injury. None of this is fully understood yet, and research is ongoing. What is fair to say is that the heart benefits appear to be partly, but not entirely, explained by weight change alone.

For people asking specifically about cardiovascular outcomes, it is worth reading about how Wegovy may benefit people with existing heart conditions, since the SELECT trial specifically recruited adults with established cardiovascular disease rather than those at general population risk.

What about other organs, does semaglutide help kidneys or liver too?

Wegovy's reach seems to extend beyond the heart. A separate body of evidence points to benefits for kidney function, with semaglutide showing reductions in kidney disease progression in trials involving people with type 2 diabetes and chronic kidney disease. This has prompted ongoing research in non-diabetic populations. If kidney health is a particular concern alongside heart health, the question of whether Wegovy is beneficial for kidney function is covered in more detail separately.

On liver health, the MHRA granted a conditional approval on 3 July 2026 for semaglutide (Wegovy) as a treatment for MASH, a form of metabolic fatty liver disease with moderate-to-advanced fibrosis. That is a distinct and new indication, and it underlines how semaglutide's effects appear to span several organ systems. Whether any of these benefits are relevant to a specific person is, again, a prescriber-level judgement that considers the full clinical picture.

The broader picture of semaglutide's effects on metabolic conditions, including how it relates to type 2 diabetes management, is explored in a related page. The treatment overview on our Wegovy information page covers licensing, eligibility and how the process works for those considering it through a private route.

Who can access Wegovy for cardiovascular reasons in the UK?

The cardiovascular indication adds a layer of nuance to eligibility. Under the weight-management licence, Wegovy is authorised for adults with BMI 30 or above, or BMI 27 to 29.9 with at least one weight-related condition. The cardiovascular risk-reduction licence applies to adults with BMI at or above 27 who have established cardiovascular disease, meaning a previous heart attack, stroke, or peripheral artery disease.

On the NHS, access follows NICE TA875 criteria, which require use within specialist weight management services for a maximum of two years. Waiting lists are long in many areas. For people who meet the clinical criteria but cannot access NHS provision quickly, a private assessment through a registered pharmacy is an alternative route. Every prescription through a legitimate service requires a clinical consultation, a qualified prescriber reviews the full picture, not just the BMI.

If cost is a factor in your thinking, private Wegovy pricing and what reputable services include are explained plainly. Wegovy's cardiovascular evidence is genuinely significant, but the right question before starting any prescription treatment is whether it suits your specific health profile, and that is exactly what the clinical consultation is for.

If you want a prescriber to assess your situation, speak to our prescribers through a free consultation with nume.